Blincyto is an English word starting with the letter B. With 2 example sentences you'll see exactly how it works in context.
Blincyto in a sentence
Context around Blincyto
- Average sentence length in these examples: 23 words
- Position in the sentence: 1 start, 1 middle, 0 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Blincyto
- In this selection, "blincyto" usually appears near the start of the sentence. The average example has 23 words, and this corpus slice is mostly made up of statements.
- Around the word, incorporated and blinatumomab stand out and add context to how "blincyto" is used.
- Recognizable usage signals include again incorporated blincyto in first and amgen s blincyto blinatumomab which. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "blincyto" sits close to words such as aabc, aacr and aacsb, which helps place it inside the broader word index.
Example types with blincyto
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
This again incorporated BLINCYTO in first-line and showed compared to their extensive historical data, a substantial improvement in overall survival. (21 words)
The only bispecific antibody currently on the market is Amgen’s Blincyto (blinatumomab), which targets CD19 and CD3 and is approved for acute lymphoblastic leukemia. (25 words)
The only bispecific antibody currently on the market is Amgen’s Blincyto (blinatumomab), which targets CD19 and CD3 and is approved for acute lymphoblastic leukemia. (25 words)
This again incorporated BLINCYTO in first-line and showed compared to their extensive historical data, a substantial improvement in overall survival. (21 words)
Example sentences (2)
This again incorporated BLINCYTO in first-line and showed compared to their extensive historical data, a substantial improvement in overall survival.
The only bispecific antibody currently on the market is Amgen’s Blincyto (blinatumomab), which targets CD19 and CD3 and is approved for acute lymphoblastic leukemia.